Boost your Grades with us today!

NURS 6630 Assessing and Treating Clients with Bipolar Disorder

NURS 6630 Assessing and Treating Clients with Bipolar Disorder

Examine Case Study: An Asian American Woman With Bipolar Disorder. You will be asked to make three decisions concerning the medication to prescribe to this client. Be sure to consider factors that might impact the client’s pharmacokinetic and pharmacodynamic processes.

ORDER A PLAGIARISM FREE PAPER NOW

At each decision point stop to complete the following:

Don't use plagiarized sources. Get Your Custom Essay on
NURS 6630 Assessing and Treating Clients with Bipolar Disorder
Just from $13/Page
Order Essay

Decision #1

Which decision did you select?

Why did you select this decision? Support your response with evidence and references to the Learning Resources.

What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources.

Explain any difference between what you expected to achieve with Decision #1 and the results of the decision. Why were they different?

Decision #2

Why did you select this decision? Support your response with evidence and references to the Learning Resources.

What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources.

Explain any difference between what you expected to achieve with Decision #2 and the results of the decision. Why were they different?

Decision #3

Why did you select this decision? Support your response with evidence and references to the Learning Resources.

What were you hoping to achieve by making this decision? Support your response with evidence and references to the Learning Resources.

Explain any difference between what you expected to achieve with Decision #3 and the results of the decision. Why were they different?

Also include how ethical considerations might impact your treatment plan and communication with clients.

 

The Case Study:

The client is a 26-year-old woman of Korean descent who presents to her first appointment following a 21-day hospitalization for onset of acute mania. She was diagnosed with bipolar I disorder.

Upon arrival in your office, she is quite “busy,” playing with things on your desk and shifting from side to side in her chair. She informs you that “they said I was bipolar, I don’t believe that, do you? I just like to talk, and dance, and sing. Did I tell you that I liked to cook?”

She weights 110 lbs. and is 5’ 5”

SUBJECTIVE

Patient reports “fantastic” mood. Reports that she sleeps about 5 hours/night to which she adds “I hate sleep, it’s no fun.”

You reviewed her hospital records and find that she has been medically worked up by a physician who reported her to be in overall good health. Lab studies were all within normal limits. You find that the patient had genetic testing in the hospital (specifically GeneSight testing) as none of the medications that they were treating her with seemed to work.

Genetic testing reveals that she is positive for CYP2D6*10 allele.

Patient confesses that she stopped taking her lithium (which was prescribed in the hospital) since she was discharged two weeks ago.

MENTAL STATUS EXAM

The patient is alert, oriented to person, place, time, and event. She is dressed quite oddly- wearing what appears to be an evening gown to her appointment. Speech is rapid, pressured, tangential. Self-reported mood is euthymic. Affect broad. Patient denies visual or auditory hallucinations, no overt delusional or paranoid thought processes readily apparent. Judgment is grossly intact, but insight is clearly impaired. She is currently denying suicidal or homicidal ideation.

The Young Mania Rating Scale (YMRS) score is 22

RESOURCES

  • Chen, R., Wang, H., Shi, J., Shen, K., & Hu, P. (2015). Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems. European Journal of Clinical Pharmacology, 71(7), 835-841. doi:10.1007/s00228-015-1855-6

Decision Point One

Select what the PMHNP should do:

Begin Lithium 300 mg orally BID

Begin Risperdal 1 mg orally BID

Begin Seroquel XR 100 mg orally at HS

Decision Point One

 SELECTED: Begin Risperdal 1 mg orally BID

RESULTS OF DECISION POINT ONE

Client returns to clinic in four weeks

Client is accompanied today by her mother who must help the client into your office, the client looks very sedated and lethargic

ORDER A PLAGIARISM FREE PAPER NOW

Client’s mother explains that “she has been like this since about a week after the last office visit”

Please include the reasons why not using the other two medications as my decision one

Decision Point Two

Select what the PMHNP should do next:

Discontinue Risperdal and start Lithium sustained release 300 mg orally BID

Decrease Risperdal to 1 mg at HS

Change Risperdal to 2 mg at HS

Decision Point Two

SELECTED : Decrease Risperdal to 1 mg at HS

RESULTS OF DECISION POINT TWO

Client returns to clinic in four weeks

Client is less sedate, less lethargic and shows symptom improvement

Young Mania Rating Scale has decreased from 22 to 16 (a bit more than a 25% decrease in symptoms)

Please include the reasons why not using the other two medications as my decision one

Decision Point Three

Select what the PMHNP should do next:

Continue at same dose of Risperdal and reassess in 4 weeks

Increase Risperdal back to 1 mg orally BID

Change to Latuda 40 mg orally daily

Decision Point Three

SELECTED: Continue at same dose of Risperdal and reassess in 4 weeks

Guidance to Student

At this point, the PMHNP may be wise to allow the client to remain at the same dose and reassess in 4 weeks. Recall that the client is of Korean descent and is positive for CYP2D6*10 allele. As a result, she may have slower clearance of Risperdal from her system, which may have resulted in higher than normal levels of Risperdal in the blood, which in turn resulted in sedation. Therefore, if we were to increase back to 1 mg orally BID, she may have the same side effects. Latuda is FDA approved for bipolar I depression, which is not the presentation we are attempting to treat. Additionally, it is quite expensive and many insurance companies will not pay for it until other agents have been attempted and failed.

Please include the reasons why not using the other two medications as my decision one

Looking for a Similar Assignment? Our Experts can help. Use the coupon code SAVE30 to get your first order at 30% off!